Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Astellas

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence (BCR) at high…

Benzinga

Pharma Giant Warns Pills Critical For Organ Transplant Patients' to Survive May Be Completely Empty in Urgent Recall

Pharmaceutical company Astellas Pharma announced two urgent recalls for vital immunosuppressive drugs, Prograf and Astagraf XL, that are used to prevent organ rejection in transplant recipients.

International Business Times

Breakthrough Treatment Veoza Receives UK Approval to Tackle Hot Flushes

Veoza distinguishes itself as a non-hormonal menopause drug that directly targets the brain to prevent hot flushes.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

A 'game-changing' new drug for hot flushes has just been approved: what does this mean for UK women?

Veoza is the new drug for hot flushes that's been approved for use in the UK with immediate effect

Woman & Home

New menopause drug to treat hot flushes given green light in UK

Women can be prescribed Veoza from January after facing decades with few treatment options

The Independent UK

‘Gamechanging’ drug to prevent hot flushes wins approval in UK

Veoza, also known as fezolinetant, is prescription-only and will be available privately from January

The Guardian - UK

Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin

Astellas Pharma won FDA approval for a rival to Apellis Pharmaceuticals' eye-disease treatment and APLS stock plunged Monday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

3 Stocks With MAJOR Growth Potential

Considering the recent robust economic indicators and growing optimism, I think fundamentally strong growth stocks América Móvil (AMX), Astellas Pharma (ALPMY), and Bruker (BRKR) could be ideal investments. Continue reading.

StockNews.com

New menopause drug for hot flashes gets FDA approval

The Food and Drug Administration has approved a new type of drug to treat hot flashes caused by menopause

The Independent UK

Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma

Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying.

Investors Business Daily

Japan foreign minister Hayashi to visit Beijing on Saturday

Japan Foreign Minister Yoshimasa Hayashi said on Friday he will visit Beijing for two days from Saturday to discuss a range of issues, including the detention of an Astellas Pharma Inc employee.

Reuters

Michael Hiltzik: Biden says he wants to bring down drug prices. His actions tell a different story

You might get the impression from the Biden administration's insulin price cut and its initiative allowing Medicare to negotiate over other pharmaceuticals that the drug pricing issue is finally being taken seriously in Washington.

Los Angeles Times

Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.

Investors Business Daily

Sutro Biopharma Stock Surges On Cancer Treatment Pact

Astellas Pharma Inc (OTC: ALPMF) and Sutro Biopharma Inc (NASDAQ:STRO) announced a strategic collaboration and licensing agreement focused on the discovery and development of immunostimulatory antibody-drug conjugates (iADC). iADCs are a next-generation modality for treating cancer and are designed to boost anti-cancer activity. They offer potential new options for patients who do not respond to existing…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold

The FDA has placed a clinical hold on Astellas Pharma Inc's (OTC:ALPMY) FORTIS Phase 1/2 trial following a serious adverse event (SAE) of peripheral sensory neuropathy in one of the trial participants. FORTIS trial is evaluating AT845, an investigational adeno-associated virus (AAV) gene replacement therapy in adults with Late-Onset Pompe Disease. The FDA has…

Benzinga

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

Twist Bioscience Corporation (NASDAQ:TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC:ALPMF) to conduct research activities to identify and optimize proprietary Twist antagonist antibodies. The antibodies will target an undisclosed checkpoint inhibitor pathway in the tumor microenvironment as potential therapeutic development candidates. Ligands in this pathway are…

Benzinga

Astellas' Menopause Drug Suffers Setback After Failed Asian Trial

After acing a pair of phase 3 trials, Astellas Pharma Inc (OTC:ALPMF) has reported the failure of fezolinetant to beat placebo in a late-stage study of patients in Asia. The study randomized 302 women in China, Korea, and Taiwan. After 12 weeks, Astellas saw numerical improvements in the rate of hot flashes from baseline…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing

Astellas Pharma Inc (OTC:ALPMF) announced topline results from the Phase 3 SKYLIGHT 4 trial investigating the long-term safety of fezolinetant in vasomotor symptoms associated with menopause (VMS). The data will support future regulatory filing submissions. The study has met its primary objectives, including safety and tolerability and improvements in endometrial health at week…

Los Angeles Times

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

National Institutes of Health

72 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.